Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications
Endocrine-Related Cancer · 01.08.2026 · 33 (8)
DOI: 10.1530/erc-25-0342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 04.08.2026. Verfasst von Luming Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong Universit…. Hauptthemen laut MEDLINE: Adrenal Cortex Neoplasms, Adrenocortical Carcinoma. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with poor survival and limited treatment options. To comprehensively characterize its molecular landscape and identify clinically relevant subtypes, we performed an integrated genomic analysis – including whole-exome sequencing, RNA sequencing, and copy number variation profiling – on 61 Chinese patients with ACC. We identified recurrent mutations in TP53 (25%), CTNNB1 (15%), ZNRF3 (10%), and MEN1 (8%). Unsupervised clustering of transcriptomic data revealed four distinct molecular subtypes: cortisol-driven (CD, 14%), immune-suppressed (IS, 40%), cell cycle-altered (CCA, 22%), and immunomodulatory (IM, 24%). The CD subtype exhibited steroidogenic pathway activation; the IS subtype showed T cell receptor downregulation and the worst disease-free survival; the CCA subtype was marked by chromosomal instability and cell cycle gene overexpression; and the IM subtype displayed enriched immune signaling and favorable outcomes. Copy number analysis further uncovered focal amplifications (e.g. TERT, CDK4) and HLA-II deletions. This study establishes a novel molecular classification of ACC, providing a framework for subtype-specific therapeutic strategies, such as CDK4/6 inhibition for CCA and immunotherapy for IM tumors, while highlighting the clinical challenges of immune-cold IS tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
- National Clinical Research Center for Metabolic Diseases (Shanghai), Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, National Research Center for Translational Medi…
- Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai, China.
ORCID-Profile: Luming Wu, Tingwei Su, Cui Zhang, Lei Jiang, Weiwei Zhou, Xu Zhong, Weiqing Wang
Zitieren
APA
Wu, L., Su, T., Zhang, C., Jiang, L., Xie, J., Zhou, W., Jiang, Y., Zhong, X., & Wang, W. (2026). Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications. Endocrine-Related Cancer, 33(8). https://doi.org/10.1530/erc-25-0342
Vancouver
Wu L, Su T, Zhang C, Jiang L, Xie J, Zhou W, et al. Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications. Endocrine-Related Cancer. 2026;33(8). doi:10.1530/erc-25-0342
BibTeX
@article{Wu2026,
author = {Wu, Luming and Su, Tingwei and Zhang, Cui and Jiang, Lei and Xie, Jing and Zhou, Weiwei and Jiang, Yiran and Zhong, Xu and Wang, Weiqing},
title = {Molecular subtyping of adrenocortical carcinoma reveals distinct subtypes with prognostic and therapeutic implications},
journal = {Endocrine-Related Cancer},
year = {2026},
volume = {33},
number = {8},
doi = {10.1530/erc-25-0342}
}
EUVIMED